Temin H M
McArdle Laboratory, University of Wisconsin, Madison 53706.
Hum Gene Ther. 1990 Summer;1(2):111-23. doi: 10.1089/hum.1990.1.2-111.
Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Furthermore, even in the very remote possibility that there is a nontherapeutic biological effect of the treatment, it is unlikely to be a harmful one. Thus, once very safe retrovirus vector-helper cell systems are constructed and in use, safety considerations should not hold up further human trials of retrovirus vectors.
利用逆转录病毒载体对人类疾病进行体细胞基因治疗是一项具有潜在重大医学益处的新技术。尽管它涉及重组DNA技术和改造后的逆转录病毒，但载体和递送系统的合理设计消除了大多数可预见的潜在风险。此外，即使在极不可能的情况下，治疗产生了非治疗性生物学效应，也不太可能是有害的。因此，一旦构建并使用了非常安全的逆转录病毒载体-辅助细胞系统，安全考量不应阻碍逆转录病毒载体的进一步人体试验。
